ACTRN12617000911392
Completed
Phase 1
A Phase I, Randomized, Double blinded, Adaptive, Single and Multiple Ascending Dose Study of the Safety and Tolerability of NPI 001 Solution in Healthy Subjects
acuity Pharmaceuticals Pty Ltd0 sites54 target enrollmentJune 21, 2017
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- acuity Pharmaceuticals Pty Ltd
- Enrollment
- 54
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Phase 2
Safety, Pharmacokinetics, Pharmacodynamics and Efficacy study of MRG-001 on Severe and Critical SARS-CoV-2CTRI/2022/01/039274Medregen LLC
Completed
Phase 2
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with PD-L1 positive recurrent or metastatic HNSCCJPRN-jRCT2080225258600
Completed
Phase 2
A Randomized, Double-blind, Adaptive, Phase II/III Study of GSK3359609 or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1 Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (study 209229)NL-OMON52820GlaxoSmithKline25
Active, not recruiting
Phase 1
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerRecurrent/Metastatic Head and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code 10065147Term: Malignant solid tumorSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-002263-99-HUGlaxoSmithKline Research & Development Ltd600
Active, not recruiting
Phase 1
A Phase II/III study of GSK3359609 in combination with pembrolizumab compared with pembrolizumab plus placebo in participants with recurrent or metastatic head and neck cancerEUCTR2019-002263-99-NOGlaxoSmithKline Research & Development Ltd315